One of today’s most impressive movers in the market is Stratera Biopharma (NASDAQ:STAB) on news of a strategic agreement. Currently, STAB stock has appreciated more than 115% on an otherwise impressive green day in the market.
A number of biotech stocks and other higher-risk equities are outperforming today, as various high-profile earnings reports roll in. Indeed, for companies looking to take a “buy the dip” approach, today has finally provided what looks like some positive momentum.
It’s worth noting Stratera is what most investors would consider a micro-cap stock. This company currently trades at a valuation of around $22 million at the time of writing. Accordingly, as a clinical-stage micro-cap pharmaceutical company, investors have a higher-risk, higher-upside bet in STAB stock to begin with.
Thus, today’s moves may not be unsurprising. However, as many investors may guess, there is a catalyst behind this move. Let’s dive into what investors are watching today with Stratera.
Why Is STAB Stock Soaring Today?
Stratera is a company focusing on providing various next-generation immune therapies. Given the pandemic world we’re living in, immune therapies are in focus right now.
However, today’s outsized move with Stratera appears to be the result of a strategic agreement the company signed with Immune Therapeutics for the rights to develop and commercialize naltrexone and met-enkephalin, two key drugs in Stratera’s pipeline.
These sorts of commercialization deals are commonplace in the biotech space. Clinical-stage companies with promising therapies or drugs often sell off interests in such drugs at an early stage to fund development of other pipeline drugs and therapies. Such appears to be the case with this deal.
The hope is that the cash flow from this transaction, which is contingent on ongoing negotiations, will fund other programs within the company. For those bullish on the research and development (R&D) capabilities of Stratera, there’s a lot to like about this deal. Today, the market is certainly taking notice. Additionally, I’ve put this stock on my watchlist right now to boot.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.